John A. Parrish, MD, proudly served in the United States Marine Corps and was a battlefield doctor in Vietnam. He is the Chief Executive Officer and co-founder of the Center for the Integration of Medicine and Innovative Technology (CIMIT), a consortium of academic and engineering research laboratories, universities and more than 40 private-sector companies. Through CIMIT, clinical investigators work to advance the standards of care for all patients through the development and the adoption of targeted medical devices and technologies.  Trained in internal medicine, dermatology and clinical research, Dr. Parrish has been recognized as a visionary and innovator who lists among his accomplishments the development of therapies to treat skin disease, including the now-common use of ultraviolet light. For two decades, Dr. Parrish served as chief of the Department of Dermatology at Massachusetts General Hospital, founding the Wellman Center for Photomedicine, the first – and now the world’s largest – multidisciplinary research group to study the effects of lasers on tissue.

A graduate of Duke University and Yale University School of Medicine, Dr. Parrish is a member of the Institute of Medicine, National Academy of Science, the National Space Biomedical Research Institute and the Defense Science Board. He is the author or co-author or more than 300 publications, including six books.

Dr. Parrish has earned the Discovery Award from the National Dermatology Foundation; the Bowditch Prize from Massachusetts General Hospital for enhancing the quality of patient care while reducing the cost of that care; the U.S. Army’s Thurman Award, honoring the late Gen. Maxwell Reid Thurman, who championed the advancement of lifesaving medical technologies within the U.S. Army; and the American Skin Association's 2011 David Martin Carter Mentorship Award, for being extraordinarily caring and effective in guiding his trainees, and 2011 Humanitarian Award, for his his wide-ranging lifetime professional contributions to the field of dermatology. He is the first individual to have received both the David Martin Carter Mentor and Humanitarian Awards in the 25 year history of the ASA.

John is the Chief Operating Officer and Technology Implementation Director at CIMIT. Before joining CIMIT in 2008, John was president of TIAX LLC and before that Senior Vice Preseident at Arthur D. Little Inc. when he managed its Technology and Innovation (T&I) business. He has spent his career in industry as a leader in technology-driven businesses, with more than 30 years of international experience focused on the accelerated development and commercialization of innovative technologies, products and services.

He received a BS in Mechanical Engineering from Rensselaer Polytechnic Institute, and an MS and PhD in Mechanical Engineering from the Massachusetts Institute of Technology. He is a frequent speaker and holds over 20 US patents on new products and manufacturing processes, including trocars and staplers for MIS, blood fluid warmers, and tendon and ligament repair methods.

Mike is an Entrepreneur in Residence at CIMIT. His primary responsibility is to lead the CIMIT Accelerator Program which is focused on finding, funding and facilitating innovations that are to be handed off to industry within twelve to eighteen months. Mike and his team work closely with the project teams to not only advance the technology, but also to develop and execute a complete strategy for getting the innovation into practice.

Mike has been working in the field of medical devices for more than 25 years; during this time he has invented or worked on products that have treated over twenty million people. He was a co-founding of Radianse, a venture-backed company that develops indoor positioning systems for hospitals. Prior to founding Radianse, Mike worked as a technical strategist for wireless solutions at Hewlett-Packard/Agilent Technologies (now Philips Medical Systems). He has helped to develop and introduce dozens of successful products, holds over 40 patents in wireless medical device communications and has ten more patents pending. Mike received a special citation from the Commissioner of the FDA for "exceptional initiative and leadership to protect the public health." He has a BSEE from The University of Michigan.

Dr. Steven Schachter attended medical school at Case Western Reserve University in Cleveland, Ohio. He completed an internship in Chapel Hill, North Carolina, a neurological residency at the Harvard-Longwood Neurological Training Program, and an epilepsy fellowship at Beth Israel Hospital in Boston, Massachusetts. He is Chief Academic Officer and Program Leader of NeuroTechnology at CIMIT and a Professor of Neurology at Harvard Medical School (HMS).

Dr. Schachter is Past President of the American Epilepsy Society. He is also past Chair of the Professional Advisory Board of the Epilepsy Foundation and serves on their Board of Directors.

He has directed over 70 research projects involving antiepileptic therapies, and published over 200 articles and chapters. He compiled the 6-volume Brainstorms series, which has been distributed to over 150,000 patients and families worldwide in several languages, and edited or written 23 other books on epilepsy and behavioral neurology. Dr. Schachter is the founding editor and editor-in-chief of the medical journal Epilepsy & Behavior.

Diane has over 25 years of experience in Research Financial Management. Before joining CIMIT in January 2010, Diane worked for Partners Research Management overseeing all financial aspects of Grants and Contracts including reporting and quality assurance. In her current role she is responsible for fiscal management, oversight, and reporting as well as the administrative operations supporting these responsibilities. 

Diane provides support and management of CIMIT’s open innovation platform CoLab. CoLab is a configurable platform that supports collaborative teams throughout the innovation cycle.

Marshall Collins is a Research Analyst with a background in Economics and Behavioral Neuroscience. Specifically, his area of focus was Health Economics and Econometrics in risk analysis.

Marshall works on the continuing development and support of the cloud-based, online platform CoLab for CIMIT. CoLab is a configurable platform that provides functionality needed to support collaborative teams in operating efficiently and effectively in navigating some portion of the innovation cycle. Over the past few years, CoLab has been adopted domestically with use from Yale and Texas Children’s hospital, as well as internationally, with portals in the UK, Singapore, and others.

Marshall also is a CRAASH Manager, a course that helps teams learn to commercialize their healthtech innovations.

Ms. Ford Carleton is the Director of Clinical Innovation for CIMIT and the Program Director for the NIBIB Point-of-Care Technology Research Center in Primary Care. She has extensive national and international experience teaching innovation methodology and leading technology innovation projects. Technology innovation projects for which she was Program Manager include the development of a physiologic monitoring patient surveillance safety net, the “Guardian Aingeal” for traditionally unmonitored hospitalized patients, in collaboration with Intelesens, and for the “Acuity Flexible Monitoring System” for general care marketed internationally by Protocol/Welch-Allyn. Her international work includes consultation with A*STAR and the Eastern Health Alliance, she has consulted for the P.D. Hinduja Hospital in Mumbai, India.

Prior to joining CIMIT, Ms. Ford Carleton was Associate Director for Research Management at Partners HealthCare, Bedside Technology Specialist in the Bioengineering Department at MGH, and a Clinical Nurse Specialist in critical care at MGH and at Beth Israel Deaconess Medical Center. She holds graduate degrees in cardiovascular nursing from University of Michigan and in Palliative Care from University of London, as well as a Masters in Public Administration from Harvard University.

Deborah Lee, MEd, is the Manager of Research Administration at CIMIT. She has 5 years of experience in research management, specializing in awards management and compliance for federally funded programs. Debbie is also is a CRAASH Manager, a course that helps teams learn to commercialize their healthtech innovations.

Prior to joining CIMIT, Ms. Lee helped develop a multi-institutional undergraduate research program in the Renal Division at the Brigham and Women’s Hospital and was a grant specialist for both the Renal and Biomedical Engineering Departments. A former teacher with a Masters in Education in Curriculum Development, Ms. Lee has also developed a number of classroom curriculums in the Boston-area.
 
Ms. Lee holds a BA in the Philosophy of Religion from Boston University, and a MEd from Boston College.

Mike is an Entrepreneur in Residence at CIMIT. His primary responsibility is to lead the CIMIT Accelerator Program which is focused on finding, funding and facilitating innovations that are to be handed off to industry within twelve to eighteen months. Mike and his team work closely with the project teams to not only advance the technology, but also to develop and execute a complete strategy for getting the innovation into practice.

Mike has been working in the field of medical devices for more than 25 years; during this time he has invented or worked on products that have treated over twenty million people. He was a co-founding of Radianse, a venture-backed company that develops indoor positioning systems for hospitals. Prior to founding Radianse, Mike worked as a technical strategist for wireless solutions at Hewlett-Packard/Agilent Technologies (now Philips Medical Systems). He has helped to develop and introduce dozens of successful products, holds over 40 patents in wireless medical device communications and has ten more patents pending. Mike received a special citation from the Commissioner of the FDA for "exceptional initiative and leadership to protect the public health." He has a BSEE from The University of Michigan.

Eric is an active member of the early-stage investor community in Boston. He sits on the Executive Committee of Mass Medical Angels and on the Screening Committee of Launchpad Ventures. Since many early-stage deals are now syndicated, he also maintains relationships with Hub Investment Group, Boston Harbor Angels and Cherrystone, among others. He has served as CEO for several biomedical companies, including Targeted Cell Therapies, Abazyme, Lumos Catheter Systems, Mulleris Therapeutics and Follica Biosciences. He began his career at Procter & Gamble and at the Boston Consulting Group. Mr. Evans holds a master’s degree in finance and public policy from the Wharton School at the University of Pennsylvania, and a bachelor’s degree in nuclear physics from Brown University.

Dr. Gupta earned his MD at Cornell University and his PhD in Computer Science at the State University of New York at Stony Brook.  In addition to serving as the CIMIT Site Miner for MGH, he is the director of the MGH Ultra-high Resolution Volume CT Lab.  An instructor in radiology at Harvard Medical School, Dr. Gupta’s clinical specialties include Cardiovascular and Neuroradiology.  Prior to joining MGH, Dr. Gupta was a Computer Scientist at GE Global Research Center in Niskayuna, NY, conducting research in medical imaging, non-destructive evaluation of aircraft engine parts, and computer vision.  He also served on the faculty of University of Southern California, Los Angeles, in the Department of Electrical Engineering Systems.

Wolfgang Krull is a Senior Operations Management Professional in the Medical Device Industry with a proven track record of leading complex business, site, operations, supply chain, and product development organizations including two successful startups. His specialties include leading Operations, Strategic Planning, Organizational Development, and Program Management to meet worldwide business, quality, and regulatory requirements.

Wolfgang spent 24 years with Hewlett Packard Medical (now Philips) in multiple functions including executive positions as Director of R&D and Director of Worldwide Manufacturing/Order Fulfillment for the Patient Monitoring Business. In these roles he was responsible for strategic development for the Bedside Patient Monitoring, Digital Telemetry, Central Monitoring, and Cath Lab product lines for critical, intermediate, and coronary care hospital markets.

In 2001, he joined start-up Visualization Technologies (VTI) as Vice President of Manufacturing and Supply Chain responsible for strategic business, process, operational, and organization improvements including initiatives in lean, cost reduction, quality improvements, and new product launch processes for Manufacturing. In 2002, VTI was successfully acquired by General Electric where Wolfgang continued as Vice President of Operations and Supply Chain.

In 2003, Wolfgang joined start-up Breakaway Imaging as Vice President of Operations and Supply Chain responsible for establishing and leading operations, supply chain, quality system, and service organizations and processes for the O-arm Imaging system. In 2007, Breakaway Imaging was successfully acquired by Medtronic and Wolfgang became the Regional Business and Site Manager for the Medtronic’s Navigation and Imaging business responsible for leading product development, operations, quality/regulatory, and factory services organizations for the O-arm business.

In addition to his CIMIT Accelerator Executive role, Wolfgang is the founder and president of Krull Enterprise Services for Operations and Supply Chain (KESSCO) providing “hands-on” management and consulting services to assist emerging, early, and mid-stage medical technology companies develop, implement, and optimize their manufacturing and supply chain operations to meet business goals. Wolfgang has been a Hewlett Packard Fellow, Chairman of the University of Massachusetts (Amherst) College of Engineering Deans Advisory Committee, and Member of the Boston University Software Engineering Advisory Committee.

Paul Magnin spent 17 years as a key contributor to Hewlett-Packard's Ultrasound Imaging business. He was the General Manager of Hewlett-Packard's Imaging Systems business from January 1996 through 1998. From 1998 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging. LightLab Imaging, a medical device start-up company, brought to market a proprietary technology that employs infrared light to make images with resolution on the micron scale for Cardiology, Endoscopy, Neurology, and Surgical Microscopy. He managed the company from the start-up phase through the sale of the company to Goodman Ltd. Subsequently he was the Founder and President of Novelis, Inc. a privately funded start-up focused on guiding therapy for Interventional Cardiology applications. Novelis was sold to Volcano Corporation in 2008.

Dr. Magnin is an advisor and board member of a number of medical device start-up companies and the Chairman of the Board of Directors of Ultrasonix Medical Corp. in Vancouver, BC. He holds over 16 patents and has authored over 20 scientific journal articles. He has been studying and working in medical imaging since 1977 while an undergraduate at Princeton University. In 1981 he completed his doctorate in Biomedical Engineering at Duke University where he was part of the Ultrasonic Imaging research team.

Paul is an experienced medical device developer, manager and entrepreneur. He is the Founder of Technology Innovators - a company that deeply researches specific medical problems, then invents solutions to those problems, prototypes and patents the solutions and finally licenses the technology to others. He is also a Co-Founder of Radianse, the real time location company, and served as the VP of R&D for that company. Prior to Radianse, he worked at Philips Medical where he was a business program manager for the cardiac resuscitation business - in this role he was responsible for leading the Marketing, Regulatory, Manufacturing, R&D, Quality and Finance teams around the ~$70M business focused primarily on defibrillators. Before this, he held various leadership positions in marketing and R&D for a diverse set of products which included physiological monitors, telemetry devices, telehealth, infusion pumps, and arrhythmia processing algorithms.

Dr. James E. Muller is the director of the Vulnerable Plaque and Patient Program. From 2005 to 2015 Dr. Muller served as CEO and then Chief Medical Officer of Infraredx, Inc. a company he founded to develop an instrument to identify vulnerable coronary plaques.  With the sale of Infraredx to Nipro, Inc., he has returned to academic medicine to develop the full range of activities necessary to improve the prevention of heart attacks.

Infraredx, Inc, successfully developed a multimodality near-infrared spectroscopy and IVUS coronary catheter that can identify the lipid-rich and presumably vulnerable coronary artery plaques that cause heart attacks.  The definitive test of this technology -- an outcomes study in over 1360 patients -- will yield results in June, 2016.  

Dr. Muller formerly served as a Professor of Medicine at the Harvard Medical School where he conducted research for over 25 years on the causes of heart attacks. In 1994, he introduced the term "vulnerable plaque" to describe those plaques likely to disrupt and cause disease onset. Dr. Muller was one of three American Co-founders of the International Physicians for the Prevention of Nuclear War (IPPNW) the organization awarded the 1985 Nobel Peace Prize.

Josh has over thirty years of in-depth experience in research, development, manufacturing, regulatory affairs and general management of medical device companies. After a research engineer position at Mass General Hospital, Josh started his commercial career as the Vice President of Research and Development for Medi-Tech, which became Boston Scientific, and helped grow that company from 20 to 500 employees. Josh then went on to start two of his own companies, including ACT Medical, Inc., an outsourcing resource for medical device companies. He built ACT to over $25 million in sales and sold it to a publicly traded company in 2000. From 2000 to 2003, Josh served as a manager of Seedling Enterprises, an incubator created to find and develop early stage medical device concepts to a point of increased value. To date, Seedling has exited three of its investments at a significant gain and has spun off three additional projects as venture-financed companies. Josh is recognized as a leading figure in the Massachusetts medical device community and currently serves on the board of several privately held companies, and chaired MassMedic, a 300+ industry trade group.

He received a BA from Harvard College and an MS in BioMechanics from MIT.

Joel Weinstein is a serial entrepreneur and an industry-recognized marketing and strategy “guru” in medical imaging and women’s health. He was a member of the founding management team of Hologic, Inc. and directed the strategies of that company’s first 12 years of meteoric growth. He has since served as a Founder of Assurance Medical, CEO of VueSonix Sensors, Andrew Technologies and Chief Marketing and Sales Officer of women’s health pioneer BioSphere Medical. Since 2001, he has also served as Founder and President of MAVEN Medical Device Strategies – a firm that nurtures growth of early and growth stage medical device companies. Joel has also served as two-term member of the Board of Directors of MassMEDIC and has served on that organization’s FDA Working Group, Start-Up Working Group and Reimbursement Working Group.

David Budil

Mark W. Grinstaff is the Distinguished Professor of Translational Research and a Professor of Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine at Boston University. He is also the Director of BU’s Nanotechnology Innovation Center, the Director of the NIH T32 Biomaterials Program, and the Associate Director for Engineering and Science at the BU Cancer Center. His inventive scientific contributions span biomedical engineering, biological engineering, nanotechnology, chemistry, and medicine, and his efforts have also led to one new FDA approved pharmaceutical and four medical device products that improve clinical care.

Dr. Gupta earned his MD at Cornell University and his PhD in Computer Science at the State University of New York at Stony Brook.  In addition to serving as the CIMIT Site Miner for MGH, he is the director of the MGH Ultra-high Resolution Volume CT Lab. An instructor in radiology at Harvard Medical School, Dr. Gupta’s clinical specialties include Cardiovascular and Neuroradiology.  Prior to joining MGH, Dr. Gupta was a Computer Scientist at GE Global Research Center in Niskayuna, NY, conducting research in medical imaging, non-destructive evaluation of aircraft engine parts, and computer vision.  He also served on the faculty of University of Southern California, Los Angeles, in the Department of Electrical Engineering Systems.

Brian B. Hoffman, MD, graduated in Medicine from McGill University. After completing residency training in Medicine and in Clinical Pharmacology he undertook a research fellowship at Duke University. He joined the faculty at Stanford University in 1981, where he went on to hold numerous leadership posts. He moved to Boston in 2003 and served as Chief of Medicine at VA Boston Health Care System from 2004 to 2008. Dr. Hoffman is currently a professor of medicine at Harvard Medical School. Dr. Hoffman is an active clinician and teacher of bedside medicine. In addition to his research publications, he has edited leading textbooks in both clinical pharmacology and in pharmacology.

Keith B. Isaacson was born and raised in Atlanta, Georgia. He graduated cum laude from Tulane University with honors in biology in 1979 and attended medical school at the Medical College of Georgia. Dr. Isaacson finished his residency in Obstetrics and Gynecology at the Ochsner Clinic in New Orleans, LA. He then finished a fellowship in Reproductive Endocrinology and Infertility at the University of Pennsylvania. He is currently board certified in Reproductive Endocrinology and general Obstetrics and Gynecology.

Dr. Isaacson was the Division Director of Reproductive Endocrinology and Infertility at the Massachusetts General Hospital from 1991 until 2001. In the fall of 2001, he left to open a center for minimally invasive gynecologic surgery and infertility at Newton Wellesley Hospital. He is currently director of the residency and fellowship for minimally invasive gynecologic surgery and infertility. Dr Isaacson is the Co-Director of the Center for Gynepathology Research at the Massachusetts Institute of Technology.

Dr. Isaacson is the immediate past president of the Society of Reproductive Surgeons (SRS) and the past president of the American Association of Gynecologic Surgeons (AAGL) and AAGL/SRS Fellowship Board of Directors and on the Board of Directors of the Society of Laparoscopic Surgeons. His recent awards include the Distinguished Surgeon Award from the American Society of Reproductive Medicine. Dr. Isaacson has focused his clinical career in advance hysteroscopic and laparoscopic procedures in women wishing to maintain their reproductive potential. He has over 75 peer reviewed publications, numerous textbook chapters and had edited two textbooks on laparoscopic and hysteroscopic surgery.

George O'Connor

Leo Otterbein earned his PhD in Physiology at Johns Hopkins University with graduate and postdoctoral training at Yale University and the University of Pittsburgh. He joined the Department of Surgery and the Transplant Institute at the Beth Israel Deaconess Medical Center in 2004 and currently has an appointment as an Associate Professor at Harvard Medical School.  His research team focuses on the protective effects of endogenously generated gas molecules including carbon monoxide and nitric oxide and their effects on the innate immune response to trauma and infection as well as the vascular proliferative effects in tissue growth and regeneration. His laboratory pursues translational research applying basic cellular and molecular mechanistic approaches to both small and large animal models.  Dr. Otterbein also brings more than fifteen years of industry experience in biotech and drug development.

Frederick Schoen, MD, PhD received his medical degree from University of Miami School of Medicine, and his doctorate (Materials Science) from Cornell University. Dr. Schoen is Professor of Pathology and Health Sciences and Technology at Harvard Medical School. Dr. Schoen’s areas of medical research include cardiovascular pathology, cardiovascular biomaterials and host-biomaterial interactions, heart valve substitutes and other technology for structural heart and vascular disease, calcification of bioprosthetic tissues, heart transplantation, and cardiovascular tissue engineering. Professor Schoen is author or co-author of over 475 manuscripts in journals and books. He serves or has served on many national and international academic and governmental advisory committees, grant review committees and editorial boards, and is consultant and scientific advisor to numerous medical device companies.